1. Pink Sheet

Sanofi-Aventis Expands Rimonabant Diabetes Program With Multiple Trials

 
• By Brooke McManus

Sanofi-Aventis is expanding its Zimulti (rimonabant) diabetes program after clinical study results showed the drug's effectiveness in reducing HbA1c is comparable to oral anti-diabetics

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet